| Jenny6833A 2005-07-30, 11:47 am |
| Hi all, this is Jenny. Dad (JensenA) has gone home.
While looking for unrelated information, I came across at least some of
what he'd been asking for in another thread. I'll be snail-mailing it
to him, and thought I'd post it here as well.
I've fixed typos, translated medical jargon (e.g., 'rhinitis') into
common terms, and left out some irrelevant junk, but it's otherwise as
written.
I hope the table comes out OK on the internet.
:-)
Jenny
****************************
The following is from a report of presentations at the 2004 Annual
Meeting of the American Urological Association (AUA) by Wayne J. G.
Hellstrom, MD, FACS.
QUOTE
Another study from Germany sought to determine patients' PDE-5
inhibitor preferences when offered all three drugs in an open-label
trial. Four hundred five patients (mean age, 59.4 years) with ED (mean
duration, 5.7 years) were exposed to an arbitrary sequence of all three
PDE-5 inhibitors. ...
The overall preference rates were Tadalifil/Cialis 35%;
Vardenifil/Levitra 29%; Sildenafil/Viagra 14%; and None 22%. ...
In reference to the reasons for preference for each respective agent,
84% claimed duration of action for Tadalifil/Cialis; 74% stated
confidence medication works every time for Vardenifil/Levitra; and 75%
cited better efficacy (hardness) for Sildenafil/Viagra.
The side effects were as follows.
S/V = Sildenafil/Viagra; V/L = Vardenifil/Levitra; T/C =
Tadalifil/Cialis
Headache 20% S/V 17% V/L 12% T/C
Indigestion 6% S/V 6% V/L 5% T/C
Stuffy nose 7% S/V 6% V/L 4% T/C
Flush 16% S/V 10% V/L 7% T/C
Muscle/back pain < 1% S/V < 1% V/L 3% T/C
Visual disturbance 6% S/V 3% V/L < 1% T/C
UNQUOTE
|